Conference Coverage

Impairment persists despite treatment in adult ADHD


 

AT APA

SAN DIEGO – Despite treatment with short- or long-acting medications, adults with attention-deficit/hyperactivity disorder report more impairment than do non-ADHD adults across several domains of daily life, and at certain times of day.

The findings, from a study presented at the annual meeting of the American Psychiatric Association, suggest that adults with ADHD have burdens that may persist despite medication.

The studies compared a cohort of 616 adults with a self-reported ADHD diagnosis and at least 6 months on medication, including short-acting stimulants, long-acting agents, or a combination of these. The researchers also recruited a comparison cohort of 200 non-ADHD adults.

“Interestingly, there was not only a difference between ADHD and non-ADHD groups, but there was also significant impairment reported among patients who are currently being treated for ADHD,” Alexandra Khachatryan, MPH, of Shire Pharmaceuticals, the study’s senior author, said in an interview. Ms. Khachatryan and her colleagues presented the findings at the APA.

For example, 44% of the ADHD respondents reported that the afternoon was the most challenging time of day, compared with 29% of non-ADHD participants (P less than .001). Mid-morning also was significantly more challenging for the ADHD group, with 26% reporting difficulties, compared with 17% of the non-ADHD cohort (P less than .01).

ADHD Thinglass/Thinkstock
The ADHD group also reported impairment across several measures of daily life function, including difficulty focusing when with friends or family (29% vs. 6%; P less than .0001), difficulty holding conversations (32% vs. 10%; P less than .0001), and being late to social events (26% vs. 7%; P less than .001).

Other statistically significant between-group differences were seen related to managing affect and emotions, sustaining effort, working memory and recall, and interpersonal relationships.

“In addition to the burden patients report across the day, they also expressed significant challenges with psychosocial functioning and managing the demands of work, social, and family life despite treatment,” said Norman Atkins, PhD, of Shire, a coauthor of the study.

A separate poster by the same research group, using the same study data from the cohort of 616 currently treated adult ADHD patients (mean age 39, 70% female) looked at self-reported impairment across daily life domains by patients under different medication regimens.

Patients in the cohort were treated with short-acting stimulants (n = 166), long-acting stimulants (n = 201), or augmentation strategies (n = 249). The researchers found that afternoons and evenings were most difficult for patients regardless of treatment approach.

Ms. Khachatryan said the study was intended to help clinicians “understand what we’re offering patients and if we’re adequately meeting the needs of patients across the day. And we found that adults experience burden across the day despite being treated, and what they report as the most challenging times of day are the afternoon and evening hours,” when work, family, and household obligations are likely to be present.

Dr. Atkins added: “From an ADHD management perspective, the key takeaway is that these impairments occur across multiple settings and are most problematic at certain times of the day. It’s important for providers to have a meaningful conversation with their patients about their day-to-day challenges to fully appreciate how ADHD impacts their functioning so they can best optimize care.”

The researchers acknowledged as limitations of their study its high number of women participants, potentially reducing the generalizability of its findings; the reliance on self-reported outcomes; and between-group differences for the ADHD and non-ADHD groups that included differences in mean age (39 vs. 43, respectively) and full-time employment status (57% vs. 42%).

The study was sponsored by Shire Pharmaceuticals, with three of its five coauthors employed by the company.

Recommended Reading

Adult ADHD: Pharmacologic treatment in the DSM-5 era
MDedge Psychiatry
Preschool ADHD diagnoses plateaued after 2011 AAP guideline
MDedge Psychiatry
Differentiating ADHD and bipolar disorder
MDedge Psychiatry
Choline and prevention of prevalent mental illnesses
MDedge Psychiatry
Recreational marijuana use should not rule out ADHD stimulant treatment
MDedge Psychiatry
Racial, ethnic differences exist ADHD treatment of Medicaid-enrolled youth
MDedge Psychiatry
ADHD medication may lower risk of motor vehicle crashes
MDedge Psychiatry
What role does asthma medication have in ADHD or depression?
MDedge Psychiatry
FDA approves generic Strattera for pediatric, adult ADHD patients
MDedge Psychiatry
ADHD – not OCD – called the key comorbidity in pediatric hoarding
MDedge Psychiatry